NEPHMEDIUM SIGNALFINANCIAL10-K

NEPH demonstrated strong operational performance with revenue growing substantially and debt levels declining meaningfully year-over-year.

The company appears to be executing well on its medical-grade water filtration strategy, with revenue growth translating into improved gross profits and a stronger balance sheet position. The substantial debt reduction combined with higher cash levels suggests improved financial stability, though investors should monitor the increase in current liabilities.

Comparing 2026-03-12 vs 2025-03-24View on EDGAR →
FINANCIAL ANALYSIS

NEPH showed robust top-line growth with revenue expanding substantially to $18.8M alongside corresponding gross profit improvements to $11.6M. The balance sheet strengthened considerably, with total debt declining by 79% to just $71K while cash positions grew to $5.4M and stockholders' equity increased to $8.4M. However, current liabilities rose notably to $2.8M, which partially offsets the otherwise positive financial trajectory.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-90%
$20K→$2K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Total Debt
Balance Sheet
-79.3%
$343K→$71K

Debt reduced 79.3% — deleveraging strengthens balance sheet and reduces financial risk.

Current Liabilities
Balance Sheet
+77.1%
$1.6M→$2.8M

Current liabilities surged 77.1% — significant near-term obligations; verify ability to meet short-term debt.

Stockholders Equity
Balance Sheet
+49.5%
$5.6M→$8.4M

Equity base grew 49.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

R&D Expense
P&L
+47.8%
$906K→$1.3M

R&D investment increased 47.8% — signals commitment to future product development, though near-term margin impact.

Cash & Equivalents
Balance Sheet
+43.6%
$3.8M→$5.4M

Cash position surged 43.6% — strong cash generation or capital raise providing significant financial cushion.

Accounts Receivable
Balance Sheet
+35.5%
$1.8M→$2.4M

Receivables surged 35.5% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Current Assets
Balance Sheet
+35.2%
$8.3M→$11.2M

Current assets grew 35.2% — improving short-term liquidity or inventory/receivables build.

Gross Profit
P&L
+33.3%
$8.7M→$11.6M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Revenue
P&L
+32.7%
$14.2M→$18.8M

Strong top-line growth of 32.7% — accelerating demand or successful expansion into new markets.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-24
ADDED
As of March 12, 2026, there were 10,644,268 shares of the registrant s common stock, $ 0.001 par value, outstanding.
The 2026 Proxy Statement will be filed within 120 days of December 31, 2025.
Food and Drug Administration (the FDA ) or other governmental agencies; we may not be able to obtain funding when needed or on terms favorable to us in order to continue operations; we may not have sufficient capital to successfully implement our business plan; we may not be able to effectively market and sell our products in new or existing markets; we may not be able to sell our water filtration products at competitive prices or profitably; we may experience increased costs and/or disruptions in our supply chain due to the imposition of U.S.
tariffs; we may encounter unanticipated internal control deficiencies or weaknesses or ineffective disclosure controls and procedures; we may not be able to obtain appropriate or necessary regulatory approvals to achieve our business plan; we may not be able to secure or enforce adequate legal protection, including patent protection, for our products; and we may not be able to achieve sales growth in key geographic markets.
Business Overview Nephros is a commercial-stage company that develops and markets high-performance water filtration solutions for points of use, with a core focus on medical-grade water filtration.
+7 more — sign up free →
REMOVED
As of March 17, 2025, there were 10,600,350 shares of the registrant s common stock, $ 0.001 par value, outstanding.
The 2025 Proxy Statement will be filed within 120 days of December 31, 2024.
Business Overview We are a commercial-stage company that develops and sells high performance water solutions to the medical and commercial markets.
Our medical water filters, mostly classified as ultrafilters, are used primarily by hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate.
Because our ultrafilters capture contaminants as small as 0.005 microns in size, they minimize exposure to a wide variety of bacteria, viruses, fungi, parasites, and endotoxins.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →